As an example, in a study conducted by Zhao et al., the A10-3.2 aptamer, a specific prostate-specific membrane antigen (PSMA) antagonist, was linked to two different miRNAs (miR-15a and miR-16-1) using the SMCC and its therapeutic effect on prostate metastatic cancer cells was analyzed. This evidence concerns the gene FOLH1 and prostatitis.